Addendum
Ibrutinib - Addendum to Commission A16-04
Report documents
-
Addendum
Ibrutinib - Addendum to Commission A16-04
Additional information
Federal Joint Committee (G-BA)
2016-07-21 A G-BA decision was published.
Project details
- Project no.
- A16-34
- Commission
- Commission awarded on 06.06.2016 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Ibrutinib (new therapeutic indication, Waldenström macroglobulinaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib (new therapeutic indication, chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ibrutinib - Benefit assessment according to §35a Social Code Book V
Status: Commission completed